All Updates

All Updates

icon
Filter
Funding
Core Biogenesis raise USD 10.5 million in Series A funding
Cell-cultured Meat
Jul 28, 2022
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Cell-cultured Meat

Cell-cultured Meat

Jul 28, 2022

Core Biogenesis raise USD 10.5 million in Series A funding

Funding

  • Core Biogenesis, a France-based upcoming biotechnology firm offering a plant-based bioproduction platform has raised USD 10.5 million in a Series A funding round led by XAnge with participation from Blue Horizon Ventures and Thia Ventures.

  • The funds are expected to be used for building an industrial-scale facility dedicated toward the production of growth factors and cytokines for the burgeoning cell therapy and cellular agriculture industry. Furthermore, it will be used for additional scientific and technical staff hires to aid expansion.

  • Core Biogenesis, founded in 2020 offers a novel green bioproduction platform for deriving plant-based recombinant proteins from the Camelina sativa oilseed plant. The company claims its patent-pending technology and animal-free growth factors allow for a more cost-effective and commercially viable cell therapy manufacturing process and can be used for a wide array of applications from therapeutics to cultivated meat.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.